Older men are more likely than women to get VEXAS syndrome, a genetic disease that arises later in life.
Thomas Barwick/Stone/Getty Images Plus
A mysterious new disease may be to blame for severe, unexplained inflammation in older men. Now, researchers have their first good look at who the disease strikes, and how often.
VEXAS syndrome, an illness discovered just two years ago, affects nearly 1 in 4,000 men over 50 years old , scientists estimate January 24 in JAMA . The disease also occurs in older women, though less frequently. Altogether, more than 15,000 people in the United States may be suffering from the syndrome, says study coauthor David Beck, a clinical geneticist at NYU Langone Health in New York City. Those numbers indicate that physicians should be on the lookout for VEXAS, Beck says. “It’s underrecognized and underdiagnosed. A lot of physicians aren’t yet aware of it.”
Headlines and summaries of the latest Science News articles, delivered to your email inbox every Thursday.
Thank you for signing up!
There was a problem signing you up.
Beck’s team reported discovering VEXAS syndrome in 2020, linking mutations in a gene called UBA1 to a suite of symptoms including fever, low blood cell count and inflammation. His team’s new study is the first to estimate how often VEXAS occurs in the general population — and the results are surprising. “It’s more prevalent than we suspected,” says Emma Groarke, a hematologist at the National Institutes of Health in Bethesda, Md., who was not involved with the study.
People with the disease may experience an assortment of symptoms across the body, including:
VEXAS tends to show up later in life — after people somehow acquire UBA1 mutations in their blood cells. Patients may feel overwhelming fatigue, lethargy and have skin rashes, Beck says. “The disease is progressive, and it’s severe.” VEXAS can also be deadly. Once a person’s symptoms begin, the median survival time is about 10 years , his team has found.
Until late 2020, no one knew that there was a genetic thread connecting VEXAS syndrome’s otherwise unexplained symptoms. In fact, individuals may be diagnosed with other conditions, including polyarteritis nodosa, an inflammatory blood disease, and relapsing polychondritis, a connective tissue disorder, before being diagnosed with VEXAS.
To ballpark the number of VEXAS-affected individuals, Beck’s team combed through electronic health records of more than 160,000 people in Pennsylvania, in a collaboration with the NIH and Geisinger Health. In people over 50, the disease-causing UBA1 mutations showed up in roughly 1 in 4,000 men. Among women in that age bracket, about 1 in 26,000 had the mutations.
A genetic test of the blood can help doctors diagnose VEXAS, and treatments like steroids and other immunosuppressive drugs, which tamp down inflammation, can ease symptoms. Groarke and her NIH colleagues have also started a small phase II clinical trial testing bone marrow transplants as a way to swap patients’ diseased blood cells for healthy ones.
Beck says he hopes to raise awareness about the disease, though he recognizes that there’s much more work to do. In his team’s study, for instance, the vast majority of participants were white Pennsylvanians, so scientists don’t know how the disease affects other populations. Researchers also don’t know what spurs the blood cell mutations, nor how they spark an inflammatory frenzy in the body.
“The more patients that are diagnosed, the more we’ll learn about the disease,” Beck says. “This is just one step in the process of finding more effective therapies.”
D.B. Beck et al . Estimated prevalence and clinical manifestations of UBA1 variants associated with VEXAS syndrome in a clinical population . JAMA . Vol. 329, January 24/31, 2023, p. 318. doi: 10.1001/jama.2022.24836.
M.A. Ferrada et al . Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis . Blood . Vol. 140, September 29, 2022, p. 1496. doi: 10.1182/blood.2022016985.
D.B. Beck et al . Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease . The New England Journal of Medicine . Vol. 383, December 31, 2020, p. 2628. doi: 10.1056/NEJMoa2026834.
Meghan Rosen is a staff writer who reports on the life sciences for Science News . She earned a Ph.D. in biochemistry and molecular biology with an emphasis in biotechnology from the University of California, Davis, and later graduated from the science communication program at UC Santa Cruz.
Our mission is to provide accurate, engaging news of science to the public. That mission has never been more important than it is today.
As a nonprofit news organization, we cannot do it without you.
Your support enables us to keep our content free and accessible to the next generation of scientists and engineers. Invest in quality science journalism by donating today.
Science News was founded in 1921 as an independent, nonprofit source of accurate information on the latest news of science, medicine and technology. Today, our mission remains the same: to empower people to evaluate the news and the world around them. It is published by the Society for Science, a nonprofit 501(c)(3) membership organization dedicated to public engagement in scientific research and education (EIN 53-0196483).
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.
Not a subscriber?
Become one now .
